Thymosin Beta-4 Protocol: How to Cycle It, Timing & What to Expect

Protocol snapshot

• Typical cycle length: 4 to 12 weeks active dosing (shorter for acute goals, longer for chronic recovery), followed by 4 to 12 weeks off
• Frequency: Daily (full-length TB4) or two to three times per week during loading, once per week during maintenance (TB-500 fragment)
• Common delivery routes: Subcutaneous injection; topical (ophthalmic applications); compounded forms vary by clinical context
• Key timing notes: Injection site proximity to target tissue is commonly prioritized; rotate sites every administration

Who This Protocol Is For

People who look into a Thymosin Beta-4 protocol are typically dealing with something that has not healed the way they expected, or they are trying to protect tissue before it breaks down further. The most common goals in real-world protocols include acute injury recovery such as tendon or muscle injuries that have stalled, chronic tissue repair for longer-running issues like tendinopathies or post-surgical healing, general anti-inflammatory support, and in specific clinical contexts, ophthalmic conditions where TB4 eye drops have been studied in human trials.

There is an important distinction to understand before looking at any protocol for this compound: full-length Thymosin Beta-4 and TB-500 are not the same thing. TB-500 is a shorter synthetic fragment of the TB4 molecule, spanning just seven amino acids compared to TB4's forty-three. The two have different half-lives and different frequency requirements. Most community protocol data refers to TB-500, while published clinical trial data covers specific full-length TB4 applications. This article covers both within the same protocol framework, noting where the two diverge.

Experience level and delivery-method preference shape the protocol in practical ways. Someone new to peptide protocols tends to start conservatively and build into the range over the first cycle. Someone with prior experience often has a clearer sense of how their body responds to a loading phase. Subcutaneous injection is the primary route for systemic use, but topical and ophthalmic applications exist for specific indications.

This compound is not appropriate for everyone. This compound is not appropriate for people with active or suspected cancer, those who are pregnant or breastfeeding, or anyone with severe liver or kidney impairment. TB4's pro-angiogenic (new blood vessel growth-stimulating) mechanism is the same property that makes it useful for tissue repair and the same one that raises concerns in oncology contexts.

How Is a Thymosin Beta-4 Cycle Structured?

A Thymosin Beta-4 cycle follows a loading-then-maintenance shape that is common to many tissue-repair peptides. The loading phase front-loads consistent early use to establish tissue saturation quickly, the maintenance phase sustains those effects at a reduced frequency, and the off-cycle break gives the system a rest before the next cycle begins. Think of it like filling a reservoir to get it operational, then running it at a lower steady flow rather than pumping in the same volume indefinitely.

For acute goals, cycles commonly run four to six weeks of active dosing. For chronic recovery or longer-running issues, the cycle extends to eight to twelve weeks. The rest period between cycles typically runs four to twelve weeks, with six weeks being the most commonly cited minimum. A widely referenced cycling rule from practitioner protocols sets the ceiling at three months of continuous active dosing, followed by a six-week break. Shorter alternatives such as six weeks on and six weeks off appear in some protocols as well.

The TB4 versus TB-500 distinction matters here because the two compounds fit different frequency patterns within the same general cycle shape. Full-length TB4 has a half-life of roughly two hours, which supports daily dosing throughout the cycle. TB-500 has a much longer half-life, commonly cited at twenty-four to thirty-six hours, which allows for a less frequent schedule. Both compounds follow the same loading-then-maintenance arc. The phase mechanics are covered in detail in the Loading and Maintenance Phases section below.

How Your Dose Is Determined

What moves a Thymosin Beta-4 dose:

• Your goal: The goal type is the primary driver of where someone lands on the range. Acute injury recovery and rapid tissue saturation sit toward the higher end during the loading phase. Chronic or long-term protective goals typically rely more on sustained frequency than on the highest possible dose. Maintenance phases trend lower than the loading phase regardless of goal.
• Experience level: Someone new to this compound commonly starts toward the lower end of the range and adjusts across the first cycle based on response. More experienced users often have a clearer sense of where they consistently land and how their body handles the loading window.
• Delivery route: Subcutaneous injection for systemic recovery is the primary route, and it requires different calibration than compounded topical or ophthalmic applications, which are scaled for specific localized indications rather than systemic goals.
• Which compound: Full-length TB4 and TB-500 require different per-injection calibration because of their different half-lives and dosing frequencies. Daily dosing and less-frequent dosing work differently, and the app handles that math. Confirming which compound is being used is a prerequisite to any meaningful dose discussion.
• Individual response: Two people running the same protocol for the same goal can land in meaningfully different places. Injury severity, baseline tissue condition, and how consistently the loading phase is maintained all affect where someone ends up.

There is no single dose that fits everyone running this protocol, which is exactly what the personalized build in the app is designed to address.

Your dose should not be a guess. The MyPeptidePal Protocol Creator takes your specific goal type, whether you are working with full-length TB4 or the TB-500 fragment, and your preferred delivery route, and builds your Thymosin Beta-4 protocol: your dose, your cycle, and your timing.

Get your protocol at mypeptidepal.ai

How Often Do You Take Thymosin Beta-4?

Frequency for this compound is directly tied to pharmacokinetics, and that picture differs sharply between full-length TB4 and TB-500.

Full-length Thymosin Beta-4 has a half-life of approximately two hours. That short clearance window means a single injection does not maintain meaningful tissue levels across a full day. Daily dosing, and in some protocols a five-days-per-week schedule with weekend breaks, is used to keep the compound consistently present. The logic is straightforward: dose frequently enough that the next administration arrives before the last one has fully cleared.

TB-500 behaves differently. Its half-life is commonly reported in the range of twenty-four to thirty-six hours, with some sources citing two to four days. That extended presence allows for a two to three times per week schedule during loading and once per week during maintenance without losing continuity of effect. A twice-weekly loading pattern, often structured as Monday and Thursday, is the most consistently reported community approach for TB-500 protocols.

Timing relative to meals is not a significant factor for subcutaneous use. Injection site proximity to the target tissue, however, is consistently raised in practitioner protocols: injecting closer to the area of injury or repair is reported to produce better outcomes, though the precise biological rationale for a systemically circulating peptide remains under discussion. Rotating injection sites across the belly, thighs, and upper arms is standard practice to prevent localized tissue irritation from repeated injections at the same spot.

Loading and Maintenance Phases

The loading phase is designed to establish rapid tissue saturation during the first weeks of the cycle. For TB-500, the most consistently reported loading pattern is twice-weekly dosing over four to six weeks. For full-length TB4, a shorter but daily loading window of around twenty days achieves a similar saturation goal given the compound's faster clearance rate.

The loading phase is not about a higher dose than maintenance. The dose tends to stay consistent across both phases. What changes is the frequency: loading runs at higher frequency to front-load the effect, and maintenance steps down to sustain it. Think of loading as filling the reservoir to operational level and maintenance as the steady-state flow that keeps it there.

For TB-500, the maintenance phase commonly drops to once-weekly dosing for four to eight weeks following the loading period. For some longer chronic-recovery cycles, twice-weekly dosing continues throughout the eight to twelve week cycle without a distinct step-down, particularly when the recovery goal requires sustained tissue support. For full-length TB4, a once-daily or five-days-per-week maintenance schedule continues the pattern established during loading.

If the protocol targets an acute injury with a short four to six week cycle, the loading phase may constitute most of the active dosing period with only a brief maintenance tail. For chronic recovery cycles running eight to twelve weeks, loading typically occupies the first four to six weeks and maintenance the remainder.

Off-Cycle Considerations

Breaks between Thymosin Beta-4 cycles are standard practice. Rest periods allow the body to return to baseline tissue signaling, prevent theoretical receptor downregulation from extended continuous exposure, and provide a natural checkpoint to assess what the previous cycle accomplished.

The most widely cited upper limit for continuous active dosing is three months, with a minimum six-week rest period to follow. This three-on, six-weeks-off structure appears across practitioner protocols and represents one of the clearest areas of consensus in an otherwise variable protocol landscape. Shorter cycles such as six weeks on and six weeks off are an alternative for users whose goal is acute rather than chronic.

Most protocols treat the off-cycle period as a genuine break rather than an opportunity to shift to a lower maintenance dose. Seasonal or injury-driven cycling is also common: running a cycle around a specific injury or surgery window, taking the required break, and returning only if there is a clear ongoing need rather than dosing continuously as a preventive measure.

What to Expect Week by Week

• Week 1 to 2: Early effects are typically subtle. Mild reduction in localized inflammation around an injury site is the most commonly reported early signal. Many users note little to nothing in the first two weeks, particularly when the goal is chronic tissue repair rather than acute injury. This is expected for a compound that works through gradual tissue signaling rather than immediate symptom relief.
• Week 3 to 4: The loading phase is in full effect. Users with acute injury goals more commonly report noticeable improvement in mobility, reduced stiffness, or a shift in the character of pain around this window. For ophthalmic use with TB4 eye drops, human clinical data shows measurable reductions in ocular discomfort and corneal staining within the four to six week window.
• Week 5 to 8: For most tissue-repair goals, this is where more meaningful change tends to accumulate. The maintenance phase is underway, and the compound's effects on cell migration and new blood vessel formation at the repair site have had time to build. Practitioners and users running eight to twelve week chronic-recovery cycles describe this period as when objective markers like range of motion or functional strength start to shift alongside subjective comfort.
• Beyond 8 weeks: For chronic applications or post-surgical recovery, the cycle may extend through twelve weeks. Cardiac applications studied in human trials showed improvements in ejection fraction (a measure of how well the heart pumps blood with each beat) and walking distance after six months, illustrating that longer recovery goals require longer timelines. The general pattern is continued gradual improvement through the end of the active cycle.

What a well-run cycle commonly looks like for someone using TB-500 for a tendon or muscle injury that has resisted normal healing is a gradual arc over eight to ten weeks: the first two weeks pass without much to report, the middle weeks bring incremental improvements in mobility and reduced acute discomfort, and by the final weeks many users report the injury site functioning at a noticeably higher level than at the start. That progression is the most commonly reported shape of a successful cycle, not a guarantee, and it varies by injury severity, dosing consistency, and protocol structure.

Individual results vary significantly based on injury type, cycle length, delivery route, and protocol consistency.

Common Protocol Mistakes

Skipping or shortening the loading phase. The loading phase exists to establish rapid tissue saturation. Starting immediately at a once-weekly maintenance frequency means the compound never reaches the consistent tissue levels that the loading window is designed to create, and the cycle underdelivers, especially for acute goals where time matters.

Confusing TB4 with TB-500 and applying the wrong frequency. This is the most consequential mistake in community protocols. The two compounds have fundamentally different half-lives, which means different frequency requirements. Applying a TB-500 twice-weekly schedule to full-length TB4 leaves significant gaps in tissue-level coverage given TB4's two-hour half-life. Applying a TB4 daily schedule to TB-500 is unnecessary and may amplify side effects without adding benefit. Confirm which compound is in the protocol before deciding on frequency.

Dosing continuously without cycling off. The three-month active dosing ceiling exists because the long-term effects of continuous use are not well characterized, and building in the standard rest period is the conservative approach. Skipping the off-cycle break to accelerate results is a poorly supported shortcut.

Ignoring injection site rotation. Repeated injection at the same site causes localized tissue irritation, swelling, and scarring over time. Rotating across the belly, thighs, and upper arms on every administration is easy to maintain with a simple rotation log and prevents a preventable problem.

Expecting results on a consumer-supplement timeline. TB4 and TB-500 work through tissue-level signaling that accumulates over weeks. Users who stop at two or three weeks because they have not noticed dramatic change are quitting before the loading phase has had time to complete its job. The four to six week minimum loading window exists for a reason.

Using unverified sources without quality assurance. Contamination, incorrect concentrations, and bacterial impurities are real risks with unverified sources. Using compounded peptides from a licensed pharmacy under provider supervision is the risk-mitigation standard that practitioner protocols consistently point to.

Thymosin Beta-4 and its fragment TB-500 are not FDA-approved for systemic injectable human use, and both are prohibited under WADA's S2 category of banned growth factors, meaning competitive athletes subject to anti-doping testing face disqualification risk.

Frequently Asked Questions

How long is a typical Thymosin Beta-4 cycle?

Most protocols run four to twelve weeks of active dosing depending on the goal: four to six weeks for acute injury recovery and eight to twelve weeks for chronic tissue repair or post-surgical contexts. A rest period of at least six weeks follows each cycle, with the commonly cited ceiling being three months of continuous active dosing before a break.

How often do you take Thymosin Beta-4?

Full-length TB4 is typically dosed daily, or on a five-days-per-week schedule, because its roughly two-hour half-life requires frequent dosing to maintain tissue-level presence. TB-500, the synthetic fragment with a much longer half-life, is commonly run two to three times per week during loading and once per week during maintenance. The right frequency depends on which compound is being used.

Does Thymosin Beta-4 need a loading phase?

Yes, for most recovery-focused protocols. The loading phase, whether daily for a short window or twice-weekly for four to six weeks depending on the compound, is designed to establish tissue saturation before stepping down to a maintenance frequency. Skipping it and starting at maintenance frequency means the compound takes significantly longer to build consistent tissue-level presence.

Do you need to cycle off Thymosin Beta-4?

Yes. The standard recommendation across practitioner protocols is a minimum six-week break after each active cycle, with the hard ceiling on continuous dosing set at three months. The off-cycle period allows the body to return to baseline tissue signaling and provides a checkpoint to assess what the previous cycle accomplished before the next one begins.

What is the difference between TB4 and TB-500 for protocol purposes?

The key difference is half-life. Full-length Thymosin Beta-4 clears the body in roughly two hours, requiring daily dosing. TB-500 is a shorter synthetic fragment with a half-life of twenty-four to thirty-six hours or longer, which allows for a two to three times per week schedule. Both follow the same general loading-then-maintenance cycle structure, but frequency within each phase differs significantly, and applying the wrong frequency for the wrong compound is one of the most common mistakes in community protocols.

Can Thymosin Beta-4 be used via non-injection delivery routes?

TB4 has clinical evidence specifically for ophthalmic use, where eye drop formulations have shown measurable effects on dry eye and corneal healing in human studies. Topical compounded forms exist for wound applications as well, with limited human data. For systemic recovery goals like tendon or muscle repair, subcutaneous injection is the primary route, and the evidence base for systemic effects via topical application is considerably thinner.

Disclaimer

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world protocols for Thymosin Beta-4 in one place.